Background {#Sec1}
==========

Hearing loss (HL) is the most common congenital sensorineural defect affecting about 1 of 500--1000 newborns worldwide. It represents a significant global health problem \[[@CR1]\]. HL has a wide spectrum of clinical manifestations: congenital or late onset, conductional or sensorineural, syndromic or non-syndromic \[[@CR2]\]. Approximately, 50% of HL is related to genetic causes \[[@CR2]\], meanwhile environmental and age-related HL account for the remaining percentage \[[@CR3], [@CR4]\]. Non-syndromic HL (NSHL) is responsible for 70--80% of all hereditary cases of HL. It, in turn, includes the autosomal recessive (AR) pattern (75%), the autosomal dominant (AD) (20--25%) and mitochondrial and X-linked HL (about 1%) \[[@CR5]--[@CR7]\]. Syndromic HL (SHL) accounts for the remaining 20--30% of genetic disorders in children \[[@CR7]\]. There are about 400 types of syndromic HL \[[@CR8]\]. HL is frequent in the Middle East and Northern African countries, with high rate of consanguinity \[[@CR9], [@CR10]\]. Iran, which has a consanguinity rate of about 38.6%, is an appropriate region for HL studies \[[@CR11]\].

Mutations in one single locus, DFNB1 locus at 13q11--12 containing *GJB2 (gap junction protein β-2)* and *GJB6* genes \[[@CR7]\], account for 50% of the ARNSHL etiology in many Western populations \[[@CR12]\]. In Iran, the prevalence of the *GJB2* mutations is variable, depending on ethnicity and geographical location \[[@CR13], [@CR14]\]. The average percentage of *GJB2* mutations, as the cause of ARNSHL, in Iran is about 18.7% \[[@CR15]\], with a higher frequency in the north (33%) and a lower frequency (4%) in the southern regions. In this region, mutations in *SLC26A4* are more frequent \[[@CR16]\]. After the exclusion of *GJB2*, recognizing the underlying gene is difficult due to the high degree of genetic heterogeneity of HL. Therefore, whole exome sequencing would be ideal to determine HL causing mutations \[[@CR17]\].

DFNB63 (OMIM 611451) was mapped to human chromosome 11q13.3-q13.4 \[[@CR18]--[@CR20]\]. This region contains the *LRTOMT* (*Leucine Rich Transmembrane and O-Methyl-Transferase*) gene \[[@CR21]\]. *LRTOMT* is a fusion gene that has alternative reading frames and only exists in primates. Human *LRTOMT* has 10 exons, of which the first two are non-coding. Five transcripts have been reported for this gene. It has two different major protein products namely LRTOMT1 and LRTOMT2, which differ in the position of the start codons (Fig. [1](#Fig1){ref-type="fig"}a) \[[@CR18]\]. *LRTOMT* is expressed in sensory hair cells with a fundamental role in auditory and vestibular functions \[[@CR22]\]. LRTOMT1 is of unknown function while LRTOMT2 participates in inactivation of catecholamine neurotransmitters. Notably, there is homology between LRTOMT2 and COMT and the majority of the residues that are involved in the substrate binding region are conserved \[[@CR23], [@CR24]\]. Accordingly, it seems that LRTOMT2 might function as a catechol-O-methyltransferase \[[@CR25]\]. Thus, LRTOMT2 has been named as COMT2. It catalyzes the transfer of a methyl group from S-adenosyl-L-methionine (AdoMet) to a hydroxyl group of catechols \[[@CR23]\]. It is expressed in sensory hair cells in the inner ear. The defects in O-methyl transferase protein have been noted to cause NSHL \[[@CR16]\]. Missense mutations cause a significant reduction in COMT2 enzymatic activity, suggesting that a defect in catecholamine catabolism underlies auditory and vestibular phenotypes \[[@CR22]\]. The 11q13.3-q13.4 includes *FGF3* (*Fibroblast growth factor 3*) gene, too. Mutations of this gene cause a form of syndromic HL (OMIM 610706), characterized by microtia, microdontia and inner ear agenesis \[[@CR26], [@CR27]\]. Patients with NSHL that are due to mutations in the *LRTOMT* gene have been found to be segregating only in the Middle Eastern, which is of a high consanguineous marriage \[[@CR20], [@CR21], [@CR26], [@CR28]--[@CR30]\]. The highest mutation frequency in this gene is reported in Tunisian families and then in Iranian, Turkish and Pakistani families \[[@CR21], [@CR22]\]. These mutations lead to severe-to-profound prelingual NSHL \[[@CR18]\]. Fig. 1**a** Two isoforms encoded by the *LRTOMT* gene: LRTOMT1 and LRTOMT2. LRTOMT1 starts in exon 3 and LRTOMT2 starts in exon 5. CDS regions are colored red. In this transcript of *LRTOMT* (NM_001145308), LRTOMT2, starts from exon 3 and ends in exon 7. **b** Pedigree of the family. The proband is marked by an arrow. **c** Pure tone audiogram of patient. Audiogram indicate sever-to-profound hearing loss in both ears. Frequency in hertz (Hz) and the hearing threshold in decibels (dB) are shown. **d** The electropherogram of the muatation in the patient (A1), deletion of 16 bp homozygously, in his father (A2) and his mother (A3) heterozygously. In the bottom of the electropherograms, the comparison of three sequence with refrence sequence is shown. The deleted 16 bp is shown in red box

The recently developed next generation sequencing (NGS) technologies such as targeted NGS (TNGS), whole genome sequencing (WGS) or whole exome sequencing (WES) have revolutionary improved disease diagnosis \[[@CR31]\] and discovery of novel disease-causing genes and variants \[[@CR32]\]. Recent advances in DNA enrichment and NGS methods have provided the opportunity for rapid and cost-effective analysis to identify pathogenic mutations in HL patients \[[@CR33]\]. WES is an acceptable method with efficient strategy to recognize disease-causing mutations in genetically heterogeneous diseases. In this method, single nucleotide variants (SNVs), small insertion/deletions, and sometimes structural changes such as copy number variations (CNVs) can be diagnosed \[[@CR34], [@CR35]\].

The aim of this study was to identify the molecular pathology of congenital HL in a four-year-old boy using WES, which led to the identification of a novel frameshift mutation.

Methods {#Sec2}
=======

Subject and clinical evaluations {#Sec3}
--------------------------------

A four-year-old boy with congenital HL from an Iranian consanguineous family (first cousins) with no history of HL was ascertained (pedigree is shown in Fig. [1](#Fig1){ref-type="fig"}b). Comprehensive family history, audiological testing such as play audiometry, tympanometry, acoustic stapedial reflex, transient /distortion product oto acoustic emission (TE/DPOAEs), auditory brainstem response (ABR), auditory steady state response (ASSR) and physical examination were performed. The parents signed written informed consent following pre-test genetic counseling. Clinical examinations did not reveal any symptoms of syndromic form of HL. The patient received cochlear implant at the age of 1 year and 5 months.

Auditory and speech performance in these cases were evaluated using the categories of auditory performance (CAP) \[[@CR36]\] scale and speech intelligibility rating (SIR) \[[@CR37]\] scale. These scales are reliable for measuring the outcome of cochlear implantation \[[@CR38], [@CR39]\]. CAP consists of 8 categories, ranging from "no awareness of environment" (CAP score 0) to "use of telephone with known users" (CAP score 7) and SIR consist of 5 categories, ranging from "unintelligible speech" (SIR score 1) to "speech intelligible to all listeners" (SIR score 5).

Molecular study {#Sec4}
---------------

### DNA extraction, *GJB2* sequencing {#Sec5}

Genomic DNA was extracted using Prime Prep Genomic DNA Extraction kit from blood (GeNet Bio, Korea), according to the manufacturer's instruction. DNA purity and concentration was determined using the Nanodrop 2000 spectrophotometer (Nonodrop 2000 Thermo Scientific, USA) and its quality was checked on 1% agarose gel.

Sanger sequencing was performed in order to exclude *GJB2* mutations and the following primers were used: F: 5′-CTCCCTGTTCTGTCCTAGCT-3′ and R: 5′-CTCATCCCTCTCATGCTGTC-3′ \[[@CR40]\]. Because there was no positive family history of HL or other cognitive disorders in the family, linkage analysis was not sought.

### Whole exome sequencing and bioinformatic analysis {#Sec6}

The Sample was sent to Macrogen (South Korea) (<https://www.macrogen.com/>) and was subjected to WES using the Novaseq 4000 platform (Illumina, San Diego, CA, USA) with 151-bp paired-end reads. In summary, genomic DNA was fragmented to prepare Illumina library and fragments were captured to target all exons, splicing sites, and flanking intronic sequences of all genes (Agilent SureSelect V6 post). All fragments were amplified and then, sequencing was performed (the mean depth of coverage was 100X for greater than 92% of the sequences). For the studied sample, 57,006,242 reads were produced, and total read bases were 8.6G bp. The GC content was 52.01% and Q30 was 93.47%. After performing WES, the released raw data were converted to the FASTQ file. Bioinformatic analysis included GATK (Genome Analysis Toolkit) (<https://gatk.broadinstitute.org/>) for variant calling, BWA (Burrows-Wheeler Aligner) (<http://bio-bwa.sourceforge.net/>) for genome alignments and variant detection (hg19, NCBI Build 38) and Picard to mark duplicate reads were used. Variant filtering was performed based on Homozygous missense, start codon change, splice site, nonsense, stop loss, and indel variants with MAF \< 1% in databases such as: dbSNP version 147, 1000 genomes project phase 3 database (<https://www.internationalgenome.org/>), NHLBI GO exome sequencing project (ESP) (<https://evs.gs.washington.edu/>), exome aggregation consortium (ExAC) (<http://exac.broadinstitute.org>) and Iranome (<http://www.iranome.ir/>).

After the filtration, the reported frameshift variant was evaluated by different in silico software tools such as PROVEAN (<http://provean.jcvi.org/>), PANTHER (<http://www.pantherdb.org/>), MutationTaster (<http://www.mutationtaster.org/>), SIFT (<https://sift.bii.a-star.edu.sg/>) and CADD (<https://cadd.gs.washington.edu/>) to predict its deleterious effect on protein in terms of function. Furthermore, the degree of conservation of this variants was assessed using NCBI BLAST of several vertebrate species \[[@CR41]\].

### Variant confirmation {#Sec7}

The candidate variant was confirmed using bidirectional Sanger sequencing. Then, co-segregation analysis was performed using exon-specific custom primers to examine segregation of genotype and HL phenotype among the family members. PCR amplification and sequencing of this variant were performed using the forward primer: 5′-GCATCCATCTCCCATGTCTT-3′ and the reverse primer: 5′-CACCATCCAGCATCAGTC-3′ in exon 6. Chromatograms were compared with reference sequence (NM_001145308), encoding a 291 residue protein (NP_001138780.1), using SeqMan software version 5.00© (DNASTAR, Madison, WI, USA). Next, this variant was investigated in the Human Gene Mutation Database (HGMD) (<http://www.hgmd.cf.ac.uk/>) and the literature to seek the novelty of the variant or its association with HL. Variant nomenclature was based on Human Genome Variation Society (HGVS) \[[@CR41]\]. The American College of Medical Genetics and Genomics (ACMG) guidelines were also used to classify this variant \[[@CR42]\]. The MEGA6 software was used to check the conservation of the mutated region in several species.

Results {#Sec8}
=======

Clinical evaluations {#Sec9}
--------------------

The proband was a four-year-old boy who showed bilateral profound NSHL, according to the audiological evaluations (Fig. [1](#Fig1){ref-type="fig"}c). Syndromic forms of HL were ruled out in this family, based on the history and clinical examination in the patient. The proband was born to a consanguineous first-cousin couple after a full-term natural delivery He showed no developmental delay or developmental regression, based on medical reports and examinations during pre-test genetic counseling. No genetic disease other than HL was evident in the related pedigree (Fig. [1](#Fig1){ref-type="fig"}). The CT scan results of Temporal Bone were normal in the patient.

Results of auditory and speech performance indicate good outcome of cochlear implantation in the patient after 3 years with CAP score of 6 (understanding conversation without lip reading) and SIR score of 5 (speech is intelligible to all listener).

Molecular findings {#Sec10}
------------------

Direct sequencing of the coding exon of the *GJB2* gene did not show any mutation. WES was applied and totally 672,262 variants were detected; one of them met the criteria for further analyses.

As a result of WES, a homozygous deletion of 16 nucleotides c.509_524del **CAGTGGCTGAAAAACT** (p.Ala170Alafs\*20) in the *LRTOMT* gene was found. It causes frameshift in exon 6 of this gene. It creates alternation of 20 amino acids downstream of the deletion and leads to an early stop codon, resulting in a truncated protein with 170 residues (versus 291 residues in the intact protein). This deletion mutation was assessed as being deleterious by Mutation Taster as well as several other prediction tools such as SIFT, PROVEAN, PANTHER (Table [1](#Tab1){ref-type="table"}). The frameshift variant was absent from dbSNP version 147, 1000 genomes project phase 3, NHLBI GO ESP, ExAC, Iranome, HGMD and Clinvar databases. It was not found in the literature, either. Ala170 and the following 20 amino acids that are modified in the mutated protein are located in a highly conserved residue of LRTOMT in multiple-species alignment (Fig. [3](#Fig3){ref-type="fig"}). It has been conserved among several species including *Pan troglodytes*, *Macaca mulatta, Mus musculus, Rattus norvegicus* and *Xenopus tropicalis*. Table 1In silico analysis of identified variants in the *LRTOMT* geneVariant/genomic\
LocationExonAmio- acid alterationDatabaseSoftwareSIFTMutation\
Taster2.0PROVEANPANTHER**c.509_524del(CAGTGGCTGAAAAACT)Frameshift mutation(Long InDel)**6A170Afs\*201000 GstateDeleteriousDisease-CausingDeleteriousDeleteriousNot foundExACScore0.894NA−4.709--Not found

The variant co-segregated with the disease in the family: heterozygous in parents, but homozygous in the patient who was the only child of the family (Fig. [1](#Fig1){ref-type="fig"}d).

According to the ACMG guideline, that its evidence is describe below, this variant is classified as a **pathogenic** variant (1 very strong, 2 Moderate and 1 Supporting criteria): It is a frameshift variant (a null variant) (**PVS1**).It is located in a mutational hot spot and/or critical and well-established functional domain (**PM1**).This variant is absent from controls (or at extremely low frequency if recessive) in Exome Sequencing Project, 1000 Genomes Project, Exome Aggregation Consortium and Iranome (local database) (**PM2**).Multiple lines of computational evidence supported the deleterious effect of the variant on the gene or gene product (conservation, evolutionary, splicing impact, etc.) (**PP3**).

The 3-D structure of the LRTOMT protein (wild-type and mutated forms) {#Sec11}
---------------------------------------------------------------------

PDB files of the wild type and mutated protein were generated from protein structure prediction server (<http://ps2.life.nctu.edu.tw/>). Then, UCSF Chimera version 1.5.3 (<https://www.cgl.ucsf.edu/chimera/>) was used to construct the 3D structure of both wild-type and the mutant forms of LRTOMT. The pictures show a comparison between wild-type and mutant protein, the catalytic domain (catechol-O-methyltransferase) that is modified in the mutant protein (Fig. [2](#Fig2){ref-type="fig"}). Fig. 2Protein structure modeling of wild-type and mutated LRTOMT. **a** the merged image of wild-type LRTOMT is shown in purple and mutanted LRTOMT in cyan. A part of the amino acid sequence has been eliminated in the mutated protein compared to the wild type protein (**b**) the catechol-O-methyltransferase domain, as a functional domain, is shown in yellow and in the figure (**c**) the modified COMT domain in the mutanted protein is defined in gray. The affected amino acids (residue 170--291) are a part of catalitic domain

Discussion {#Sec12}
==========

Hearing loss (HL) is a common sensorineural disorder, with an incidence of 1 in every 500--1000 children \[[@CR43]\]. NSHL is a highly genetically heterogeneous neurosensory disorder with over 163 known genes (<http://hereditaryhearingloss.org/>) \[[@CR44]\]. Although mutations in the *GJB2* gene has been known to be the most common cause of ARNSHL in Iran (about 18.5% of HL cases), the role of other genes is remains to be illuminated \[[@CR15], [@CR45], [@CR46]\]. Lack of accurate DNA diagnostics represents a real challenge for NSHL diagnosis and genetic counselling \[[@CR47]\]. In this regard, NGS has addressed this problem with generation of huge data from our genes in a rather short time \[[@CR48], [@CR49]\].

In Iran, HL ranks second after intellectual disability \[[@CR15]\]. To date, few studies have been performed on *LRTOMT* mutations in Iran and frequency of these mutations is not exactly known among Iranian ARNSHL patients \[[@CR28], [@CR50]\]. So far, about 20 pathogenic mutations have been reported in the *LRTOMT* gene (Table [2](#Tab2){ref-type="table"}). The human *LRTOMT* gene (the DFNB63 locus) is located on the chromosome 11q13.2-q13.4 and encodes the LRTOMT protein. The locus DFNB63 was firstly mapped to the long arm of chromosome 11 by *Kalay* et al*,* who reported a five-generation Turkish family to be linked to this region \[[@CR18]\]. Findings indicated that mouse *Lrrc51* and *Tomt* are two separate genes encoding 2 different proteins, and that human *LRTOMT* gene is a larger fusion gene with two different transcripts \[[@CR21]\]. The LRTOMT2 (residues 79 to 291) protein has a transmembrane catechol-O-methyltransferase (COMT) domain and is also known as COMT2, which is highly expressed in sensory hair cells and the vestibular organs of the inner ear \[[@CR22]\]. The most important COMT domain is identified in the generic COMT protein that catalyzes the transfer of a methyl group getting from S-adenosyl methionine to catecholamines. It is associated with inactivation of catecholamine neurotransmitters like norepinephrine, dopamine and epinephrine \[[@CR23], [@CR57]\]. In a study in 2008, the mouse model of *Comt2* mutation was generated and it was shown that mutation in this gene leads to profound HL and vestibular defect \[[@CR22]\]. By using a zebrafish model, *Erickson* et al in 2017 showed that the defect in auditory and vestibular systems due to mutations in *LRTOMT* gene. It led to a lack of mechanotransduction (MET), a process in which sensory hair cells convert mechanical energy such as vestibular and auditory stimulation to electrical signals \[[@CR58]\]. The *TMC* (*Transmembrane channel-like*) gene appears to be the most promising candidates to be the precursor of MET channel \[[@CR59]--[@CR62]\]. In humans, mutations in *TMC1* gene are responsible for both recessive (DFNB7/11) and dominant (DFNA36) forms of NSHL \[[@CR63]\]. Using the mercury mutant zebrafish, as a model of DFNB63, *Erickson* reported that *LRTOMT* is required for trafficking TMC proteins to the hair bundle \[[@CR58], [@CR64]\]. Table 2Overview of all LRTOMT mutations so far identifiedVariantCodon numberExon numberPhenotypeReferencePopulationp.Leu16Pro164Prelingual HLDu (2008) \[[@CR22]\]Iranianp.Ala29Serfs\*54294NAAhmed (2008) \[[@CR21]\]Turkishp.Met34Ilu345HL, non-syndromicBabanejad (2012) \[[@CR28]\]Iranianp.Ser35Serfs\*13355Sensorineural HLVanwesemael (2011) \[[@CR51]\]Iranianp.Glu40Asp405Prelingual profound HLBabanejad (2012) \[[@CR28]\]Iranianp.Arg41Trp415NABabanejad (2012) \[[@CR28]\]Iranianp.Arg52Trp525Non-syndromic HLWang (2017) \[[@CR52]\]Pakistanip.Arg54Gln545Prelingual moderateIchinose (2015) \[[@CR53]\]Japanesep.Arg70X705Non-syndromic HLRiahi (2014) \[[@CR54]\]Iranianp.Tyr71X715Prelingual HLDu (2008) \[[@CR22]\]Iranianp.Glu80Asp805Non-syndromic HLBabanejad (2012) \[[@CR28]\]Iranianp.Arg81Gln815Non-syndromic HLAhmed (2008) \[[@CR21]\]Tunisianp.Arg81Trp815Non-syndromic HLBabanejad (2012) \[[@CR28]\]Iranianp.Phe83Lue835NAMarková (2016) \[[@CR55]\]Czechp.Trp105Arg1055Non-syndromic HLAhmed (2008) \[[@CR21]\]Tunisianp.Glu110Lys1105Non-syndromic HLAhmed (2008) \[[@CR21]\]Tunisianp.Tyr111X1115Non-syndromic HLDu (2008) \[[@CR22]\]Iranian**p.Ala170Alafs\*201706Non-syndromic HLThis studyIranian**p.Ilu188Thrfs\*71887Prelingual moderateIchinose (2015) \[[@CR53]\]Japanesep.Arg219X2197Severe-profound NSHLSloan-Heggen (2016) \[[@CR56]\]Not defined*NA* Not Available

In several studies, it has been reported that NSHL due to mutations in the *LRTOMT* gene are more likely to be assigned to the LRTOMT2 (COMT2) region rather than LRTOMT1 \[[@CR28], [@CR51]\]. These findings indicate mutations in *LRTOMT2* are associated with hair cell defects and lead to severe-to-profound NSHL \[[@CR21], [@CR29], [@CR30], [@CR53]\]. Patients with mutations in the *LRTOMT* gene have been reported exclusively from the Middle Eastern consanguineous families \[[@CR19], [@CR20], [@CR28], [@CR50]\]. The majority of reported mutations occurred in exon 5 and 7 of the *LRTOMT2* coding region. Therefore, this region might be a mutational hot spot in the *LRTOMT* gene \[[@CR9], [@CR53]\].

In this study, a consanguineous family with a son suffering from bilateral sever-to-profound HL and negative for *GJB2* gene mutations was selected for further study using WES. As a result, a novel long deletion variant (16 bp deletion) in the exon 6 of *LRTOMT* gene ([NM_001145308](http://www.ncbi.nlm.nih.gov/nuccore/NM_001145309)) was found homozygously in the patient and heterozygously in the parents. It is a novel frameshift mutation (deletion of 16 nucleotides) in the *LRTOMT* gene, which has dual reading frames (ENST00000307198.7). In this transcript of *LRTOMT* gene, LRTOMT2 starts in exon 5 and ends in exon 7. The main portion of the catalytic domain (residues 79--291) of LRTOMT2 is eliminated as a result of this mutation (Fig. [2](#Fig2){ref-type="fig"}). The premature stop codon (20 codons after the position of the deletion) is predicted to result in a truncated protein with impaired function or no protein production, possibly because of nonsense mediated mRNA decay. The mutation region is a partly conserved in human and mice (Fig. [3](#Fig3){ref-type="fig"}), suggesting that the eliminated region is important for the catalytic functions of the enzyme. Fig. 3The modified region (5 deleted amino acids shown in the red box and the folowing 20 residues that are changed due to the frameshift mutation) is located in a highly conserved region among species

Evaluation of auditory and speech performance in this study is in line with those of previous studies, suggesting that patients with *LRTOMT* mutations show good auditory performance after cochlear implant surgery \[[@CR65]\].

Conclusions {#Sec13}
===========

In conclusion, our results suggest that mutations in the *LRTOMT* gene result in alterations in the LRTOMT2 (COMT2) protein and might be involved in sever-to-profound NSHL. The gene should be studied in a larger population of families in Iran for a more thorough understanding of its role in causing HL. This study showed that exome sequencing is an efficient molecular diagnostic method for ARNSHL as an extremely heterogeneous genetic disorder.

HL

:   Hearing loss

ARNSHL

:   Autosomal recessive non-syndromic hearing loss

WES

:   Whole exome sequencing

ACMG

:   American College of Medical Genetics and Genomics

AR

:   Autosomal recessive

AD

:   Autosomal dominant

LRTOMT

:   Leucine Rich Transmembrane and O-Methyl-Transferase

COMT

:   Catechol-O-methyltransferase

OMIM

:   Online Mendelian Inheritance in Man

WGS

:   Whole genome sequencing

NGS

:   Next generation sequencing

TNGS

:   Targeted next generation sequencing

SNV

:   Single nucleotide variants

CNV

:   Copy number variants

CAP

:   Categories of Auditory Performance

SIR

:   Speech Intelligibility Rating

BWA

:   Burrows-Wheeler Aligner

GATK

:   Genomic Analysis Toolkit

MAF

:   Minor Allele Frequency

NHLBI

:   National Heart, Lung, and Blood Institute

ESP

:   Exome Sequencing Project

ExAC

:   Exome Aggregation Consortium

SIFT

:   Scale-invariant feature transform

CADD

:   Combined Annotation Dependent Depletion

NCBI

:   National Center for Biotechnology Information

BLAST

:   Basic Local Alignment Search Tool

PCR

:   Polymerase chain reaction

HGMD

:   Human Gene Mutation Database

HGVS

:   Human Genome Variation Society

PDB

:   Protein data bank

MET

:   Mechanotransduction

**Publisher's Note**

Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

We take this opportunity to express our special thanks to the staff at the Isfahan Cochlear Implantation Center and also to the patient and family.

Study design: MAT; Enrolled the patient and contributed to clinical diagnoses and report writing: MS, MHN, HA; Data analysis and interpretation: MAT, AS, SN1, MSF, SN2, ZN; Manuscript preparation: AS, SN1, ZN; critically reviewed by MAT. All authors have read and approved the manuscript.

This work was financially supported by Isfahan University of Medical Sciences. Whole exome sequencing and its data collection and data analysis were supported by Isfahan University of Medical Sciences (grant NO.396133 and NO.394805). The funding bodies played no role in in study design and writing the manuscript.

The raw datasets generated and/or analyzed during the current study are not publicly available because it is possible that individual privacy could be compromised, but are available from the corresponding author on reasonable request.

The study was approved by the Review Board of Isfahan University of Medical Sciences (grant no: 396133 and 394805). Written informed consent was obtained from all of the participants in the study and a written consent to participate was obtained from the parents of the patient (younger than the age of 16).

Written informed consent for publication of clinical details and clinical images was obtained from the all of the participants and from the parents the participant under the age of 18.

The authors declare no conflict of interest.
